Risk factors for Kaposi's sarcoma associated herpesvirus (KSHV) DNA in blood and in saliva in rural Uganda

Angela Nalwoga[1,2], Marjorie Nakibuule [1], Vickie Marshall[3], Wendell Miley[3], Nazzarena Labo[3], Stephen Cose[1,2], Denise Whitby[3*], Robert Newton[1,4*]

*Contributed equally

1. MRC/UVRI and LSHTM Uganda Research Unit, Entebbe; Uganda
2. London School of Hygiene & Tropical Medicine, London; United Kingdom
3. Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD; United States of America
4. University of York, York; United Kingdom

Corresponding author

Angela Nalwoga

MRC/UVRI and LSHTM Uganda Research Unit

P.O Box 49 Entebbe Uganda

Plot 51-59 Nakiwogo road

Angela.nalwoga@mrcuganda.org, angelanalwoga@gmail.com

Telephone: +256417704000

Summary: HHV8 shedding in saliva is associated with viral transmission while viral detection in blood is associated with disease pathogensis. Our data shows that children may be a major transmission source and malaria could play a role in susceptibility to infection.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Abstract

Introduction

Detectable KSHV DNA in blood and increased antibody titres may indicate KSHV reactivation, while transmission of KSHV occurs via viral shedding in saliva.

Methods

We investigated risk factors for KSHV DNA detection by real-time PCR, in blood and viral shedding in saliva, in 878 people aged 3 to 89 years of both sexes in a rural Ugandan population cohort. Helminths were detected using microscopy and malaria parasitaemia was identified using rapid diagnostic tests. Regression modelling was used for statistical analysis.

Results and discussion

KSHV viral load in blood did not correlate with viral load in saliva, suggesting separate immunological control within each compartment. The proportion of individuals with detectable virus in blood was 23% among children aged 3-5 years , 22% among 6-12 years old, thereafter reducing with increasing age. The proportion of individuals with detectable virus in saliva increased from 30% in 3-5 year old children to 45% in those aged 6-12 and decreasing subsequently with increasing age. Overall, 29% of males shed in saliva compared to 19% of females (p = 0.008). Together, these data suggest that young males may be responsible for much of the onward transmission of KSHV. Individuals with a current malaria infection had higher levels of viral DNA in blood (p = 0.031) compared to malaria uninfected individuals. This suggests that malaria may lead to KSHV reactivation, thereby increasing transmission and pathogenicity of the virus.

Key words: Kaposi’s sarcoma herpesvirus DNA; Risk factors; Uganda

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Introduction

Kaposi's sarcoma-associated herpesvirus (KSHV) causes Kaposi's sarcoma (KS), multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL) (1-6). Prevalence of KSHV and incidence of KS both vary geographically, (7-9) and are endemic in sub-Saharan Africa (10, 11) .

Salivary exchange is the main route of transmission of KSHV, normally occurring in early childhood and increasing with age (12-15). In a rural population cohort in Uganda (the General Population Cohort – GPC), for instance, we have reported KSHV infections in children as young as one year (11, 16). In addition to viral shedding in saliva, viral DNA detection in blood and increased antibody titres to lytic antigens are markers of frequent KSHV reactivation (13). KSHV-associated oncogenesis and progression of dieases, as well as virus transmission, are all thought to be related to virus reactivation (17).

Viral DNA detection in blood has been associated with KS disease risk and progression (18-21). Additionally, treatment of AIDS-KS patients with cART has been shown to reduce KSHV load in blood to undetectable levels (18, 22). Determinants of KSHV DNA detection in blood among KSHV seropositive people in the general population is not well understood. Viral load in plasma and PBMCs has been reported mainly in high-risk groups such as HIV infected individuals and patients with KSHV related diseases (18, 23-27). A few studies have reported KSHV viral load in blood donors (adults) in non-endemic areas (28-30) and a study reported plasma viral load in a population-based HIV survey in an endemic area (31).

Environmental factors may contribute to high KSHV transmission in endemic areas. We have previously shown that KSHV seroprevalence is associated with malaria parasitaemia (16), higher malaria antibody titres (32) and helminth infections (33, 34). We and others have reported that KSHV shedding in saliva is more common in males compared to females (35,

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

36), but no study has investigated KSHV viral load in both blood and saliva in the same individuals within a population- based study in a KSHV endemic area.

This study investigated KSHV viral DNA detection in PBMCs and saliva in KSHV seropositive individuals aged 3 to 89 years from the General Population Cohort (GPC) – a longstanding cohort in rural south-western Uganda. We also determined the risk factors associated with viral DNA detection and levels in PBMCs and in saliva, and the relationship between viral DNA detection in PBMCs and saliva and KSHV antibody levels in plasma.

Methods

Study population and ethical approvals

This work was carried out within the General Population Cohort (GPC). The GPC is a community-based cohort of 22,000 people in 25 adjacent villages in south-western Uganda. It was established in 1989 to carry out HIV research; participants from the GPC have been followed ever since. Between July 2017 and November 2017, we nested a cross-sectional study within the GPC enrolling 975 KSHV seropositive (tested previously (32)), HIV negative individuals aged three to eighty-nine years. Participants were selected randomly after stratification for age, sex and household. Blood, stool and saliva samples were collected from these individuals. Peripheral blood mononuclear cells (PBMCs) and plasma were obtained from blood for immunological and virological analyses. Stool samples were used for helminth diagnosis while saliva was used for KSHV viral DNA detection and quantification. Socio-demographic data were collected using standard questionnaires. This study was approved by the UVRI-Research and Ethics Committee (REC) (reference number: GC/127/16/09/566), the Uganda National Council for Science and Technology (UNCST) (reference number: HS2123) and LSHTM Ethics Committee (reference number: 11881). Written informed consent was obtained from all adults aged 18 years and above. Parents or guardians consented for children below 18 years, additionally, children aged 8-17 years provided written assent.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Laboratory procedures

KSHV DNA was quantified in PBMCs and saliva from 878 KSHV seropositive individuals. A pellet of about two million PBMCs and saliva pellets were processed for DNA extraction. Study participants were instructed to rinse with 5mL of Listerine mouthwash, empting it, as well as saliva in a falcon tube. Aliquots (of 1mL each) of saliva were spun at 13,000rcf for 10 minutes to form saliva pellets. Thereafter the supernatant was removed and the saliva pellet stored at -80°C. Genomic DNA was extracted from PBMCs and saliva pellets using a QIAamp blood kit (Qiagen, Valencia, CA), following the manufacturer's instructions. KSHV DNA was quantified using real-time PCR, following procedures previously reported (13, 37, 38). KSHV DNA was detected using primers and a probe specific to the K6 gene region (39). Additionally, the number of cellular equivalents in PBMCs were determined using a quantitative assay specific to human endogenous retrovirus 3 (ERV-3) (39), which is present in two copies per genomic cell. Raw copies were reported for saliva KSHV DNA. Samples were amplified in triplicate; the samples that were positive in one or two reactions in the KSHV K6 assay were designated as qualitative positives. The sensititivity of the K6 assay is 3 copies.

Using an in house Luminex assay and ELISA, previously reported (40-42), plasma samples were tested for IgG antibody levels to the KSHV K8.1 (lytic) and ORF73 (latent) antigens. The ELISA was used to confirm serostatus while the Luminex assay was used to determine antibody levels, due to its wider dynamic range. Malaria parasitemia was diagnosed using rapid diagnostic tests (RDT) (ONE STEP Malaria HRP-II (P.f) and pLDH (Pan) Antigen Rapid Test). A single stool sample was provided by each participant. This was analysed for helminths (*Schistosoma mansoni*, *Ascaris lumbricoides*, *Tichuris trichiura*, *Trichostrongylus spp* and hookworm) using the Kato Katz microscopy method following the manufacturer’s instructions. Details of this procedure have been reported elsewhere (43, 44).

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Statistical analysis

Statistical analysis was carried out using STATA version 13 (Statacorp, College Station, Texas USA). Graphs were drawn using STATA and GraphPad Prism version 6. Qualitative positive samples were given a constant value of 0.04 for saliva and 0.5 for PBMCs, which were below the values of the lowest qualified samples for quantitative analysis. Viral load levels were $\log_{10}$ transformed. First, risk factors associated with viral DNA detection (as a categorical outcome variable) in saliva and blood, separately, were obtained using logistic regression modelling. Thereafter, risk factors associated with increasing levels of viral DNA (as a continuous outcome variable) in saliva and in blood, separately, were determined using linear regression modelling. Likelihood ratio tests were used to select the best fit models.

Results

Study participants' characteristics

We tested 878 individuals for KSHV viral DNA; 49% (410/834) were males, while 3% (27/840), 11% (95/840), 13% (110/840), 8% (67/840), 17% (139/840), 14% (121/840), 14% (118/840), 9% (74/840) and 11% (89/840) were aged 3-5, 6-12, 13-18, 19-25, 26-35, 36-45, 46-55, 56-65 and 66-89 years respectively (Table 1). The proportion of individuals with malaria parasitaemia was 4% (34/834) overall and 11% (13/120) among children 3-12 years. Previously we have reported an annual malaria prevalence of 18% in the same population (16). The lower prevalence of malaria infection in this study might be attributed to sample collection during the dry season. The prevalence of helminths was as follows: Hookworm was the most prevalent at 15% (104/686), followed by *Schistosoma mansoni* and *Ascaris lumbricoides* at 1% (8/686) each and *Trichuris trichiura* at 0.1% (1/686). We may have slightly underestimated the true prevalence of helminths, because a single, rather than triple sample test, was used.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Blood and saliva KSHV DNA detection and levels of viral DNA

We did not observe a correlation between KSHV DNA copy numbers in PBMCs and DNA copy numbers in saliva (Figure 1). The proportion of individuals with detectable viral DNA in saliva was higher than the proportion of people with the detectable viral DNA in PBMCs (Figure 2a and 2b). Children had the highest proportion of detectable viral DNA in PBMCs (Figure 2a) and in saliva (Figure 2b), decreasing with increasing age in adults. The trend was similar for females and males, with males having higher proportions of detectable viral DNA in saliva.

Associations between risk factors and KSHV DNA in PBMCs

The proportion of individuals with detectable viral DNA in PBMCs decreased with increasing age; this trend was significant even after adjusting for sex and parasite infections (Table 2). Individuals infected with malaria parasites had higher levels of KSHV DNA in blood compared to malaria uninfected individuals (adjusted regression coefficient 0.79 (0.07,1.50), p=0.031) (Table 3). We observe no statistically significant associations with other measured risk factors including age, sex, hookworm and *S. mansoni* infections (Table 3).

Associations between risk factors and KSHV DNA in saliva

Overall, males had a higher risk of shedding viral DNA compared to females; adjusted Odds Ratio 1.63 (1.14, 2.34), p=0.008 (Table 4). Similar to PBMCs, the proportion of shedders in saliva diminished with increasing age, even after adjusting for sex and parasite infections p=0.0001 (Table 4). Additionally, compared to females, males had higher levels of KSHV DNA in saliva (adjusted regression coefficient 0.46 (0.05,0.87), p=0.027) (Table 5).

KSHV DNA detection and antibody levels

Individuals with detectable viral DNA in PBMCs (Supplementary Figure 1a) and in saliva (Figure 1b) had higher IgG antibodies to the K8.1 antigen (p<0.0001), as previously reported

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

(13). There was no difference in IgG antibodies to ORF73 antigen between individuals with or without detectable viral DNA in the blood (Supplementary Figure 1c) or in saliva (Supplementary Figure 1d).

Discussion

This is the first population-based study to report on presence and levels of KSHV viral DNA in blood and saliva in apparently healthy people across the lifecourse. The proportion of individuals with detectable viral DNA in saliva was higher than the proportion of individuals with detectable viral DNA in blood, consistent with previous reports (22, 45-47). We have previously reported KSHV and EBV DNA shedding in saliva of children and their mothers in Uganda and noted that EBV DNA was shed more frequently and at higher levels than KSHV (38).

In this study, we observed no correlation between levels of KSHV DNA in blood and in saliva. Detection of KSHV DNA in blood and in saliva may reflect reactivation of the virus or an initial infection that manifests with lytic replication. Viral shedding in saliva leads to transmission of the virus (13), while viral load in blood has been implicated in disease risk and progression (18, 23). The lack of a correlation between blood and saliva viral DNA suggests that the mechanisms for reactivation of the virus in blood and in saliva may be different. This may imply that distinct immune control measures are required to prevent viral reactivation in the different compartments. For insistence, IgA production in saliva may be important for viral control in oral fluids, while T and NK cell responses may play a more pivotal role in the control of viral reactivation in peripheral blood. Alternatively environmental factors such as plant derrivates that have been shown to reactivate KSHV *in vitro* (48) may play a role in viral reactivation in oral fluids if chewed. Studies of immune correlates of KSHV DNA detection in saliva and PBMC are therefore warranted.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

The proportion of KSHV DNA detected in blood and saliva was highest in children, compared to adults. Previous studies have reported a high risk of KSHV seropositivity in children born to KSHV seropositive mothers (13, 35, 49). However, seropositivity in children whose mothers were seronegative has also been reported (49, 50). Our current study suggests that siblings or playmates may also be a major source of transmission to uninfected children.

High viral load among children could be associated with co-infections that are very prevalent in childhood such as malaria; we also observed the highest prevalence of malaria parasitaemia in the same age group. We showed that participants with malaria parasitaemia have higher levels of KSHV DNA in blood compared to those uninfected with malaria. This is the first study to relate malaria parasitaemia directly with KSHV load in blood. We have previously reported associations between malaria (parasitaemia and antibodies) and KSHV seroprevalence (16, 32-34). Results from the current study support a potential role of malaria in KSHV pathogenesis. The mechanisms for the association between malaria and KSHV viral load could include immunomodulation and dysfunction associated with repeated malaria infections (51, 52).

In the present study, males (both men and boys) were more likely to shed KSHV DNA in saliva and had higher levels of viral DNA compared to females. This is consistent with previous studies by us and others (31, 36, 38). Sex differences in immune control of KSHV infection might contribute to the higher risk of KS in men (53, 54). These findings warrant further study.

We have previously reported that high KSHV K8.1 antibody titres are associated with and predictive of KS risk (55). In the current study, we have observed that people with detectable viral DNA in both blood and saliva have higher IgG antibody levels for K8.1 but not ORF73, compared to individuals without the detectable viral DNA. This association confirms our

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

previous hypothesis (55) that increased lytic antibody levels reflect more frequent KSHV reactivation.

In summary, our data are consistent with high rates of KSHV transmission in rural Uganda. This might be partly attributed to parasite co-infections such as malaria which interfere with immune control, or make uninfected children susceptible to infections. Studies investigating the mechanism through which malaria affects KSHV are required. Additionally, characterisation of protective immune responses to KSHV is needed to inform vaccine development and to develop strategies to lower KSHV transmission in endemic areas.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Acknowledgement

We acknowledge the study participants from Kyamulibwa, Kalungu district. We recognise the General Population Cohort (GPC) and Clinical Diagnostic Laboratory services (CDLS) teams at MRC/UVRI who participated in data and sample collection.

Disclaimer

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Funding

This research was partially funded by the African Partnership for Chronic Disease Research (APCDR), University of Cambridge, United Kingdom. It has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract Number. HHSN261200800001E. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute. It also received support from the Makerere University/UVRI Centre of Excellence for Infection and Immunity Research and Training (MUII-plus). MUII-plus is supported through the DELTAS Africa Initiative (Grant no. 107743). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA), and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant no.107743) and the UK Government. The MRC/UVRI and LSHTM Uganda Research Unit is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.

All authors have declared no conflict of interest.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

References

1. Schulz TF. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). The Journal of general virology. 1998;79 (Pt 7):1573-91.
2. Sunil M, Reid E, Lechowicz MJ. Update on HHV-8-Associated Malignancies. Current infectious disease reports. 2010;12(2):147-54.
3. Chang Y, Moore PS. Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. Infectious agents and disease. 1996;5(4):215-22.
4. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. The New England journal of medicine. 1995;332(18):1186-91.
5. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276-80.
6. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (New York, NY). 1994;266(5192):1865-9.
7. Rohner E, Wyss N, Trelle S, Mbulaiteye SM, Egger M, Novak U, et al. HHV-8 seroprevalence: a global view. Systematic reviews. 2014;3:11.
8. Weiss RA, Whitby D, Talbot S, Kellam P, Boshoff C. Human herpesvirus type 8 and Kaposi's sarcoma. Journal of the National Cancer Institute Monographs. 1998(23):51-4.
9. Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma. Cancer letters. 2011;305(2):150-62.
10. Dedicoat M, Newton R. Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. British journal of cancer. 2003;88(1):1-3.
11. Newton R, Labo N, Wakeham K, Miley W, Asiki G, Johnston WT, et al. Kaposi Sarcoma-Associated Herpesvirus in a Rural Ugandan Cohort, 1992-2008. The Journal of infectious diseases. 2018;217(2):263-9.
12. Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC monographs on the evaluation of carcinogenic risks to humans / World Health Organization, International Agency for Research on Cancer. 1997;70:375-492.
13. Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, Ndlovu B, et al. Mother-to-child transmission of human herpesvirus-8 in South Africa. The Journal of infectious diseases. 2004;190(6):1068-75.
14. Minhas V, Crabtree KL, Chao A, M'Soka T J, Kankasa C, Bulterys M, et al. Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area. American journal of epidemiology. 2008;168(3):311-20.
15. Whitby D, Luppi M, Sabin C, Barozzi P, Di Biase AR, Balli F, et al. Detection of antibodies to human herpesvirus 8 in Italian children: evidence for horizontal transmission. British journal of cancer. 2000;82(3):702-4.
16. Nalwoga A, Cose S, Nash S, Miley W, Asiki G, Kusemererwa S, et al. Relationship between Anaemia, Malaria Co-infection and Kaposi Sarcoma-associated Herpesvirus (KSHV) Seropositivity in a Population-based Study in Rural Uganda. The Journal of infectious diseases. 2018.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

17. Aneja KK, Yuan Y. Reactivation and Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus: An Update. Frontiers in microbiology. 2017;8:613.
18. Broccolo F, Tassan Din C, Vigano MG, Rutigliano T, Esposito S, Lusso P, et al. HHV-8 DNA replication correlates with the clinical status in AIDS-related Kaposi's sarcoma. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2016;78:47-52.
19. Engels EA, Biggar RJ, Marshall VA, Walters MA, Gamache CJ, Whitby D, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. Aids. 2003;17(12):1847-51.
20. Jary A, Leducq V, Palich R, Gothland A, Descamps D, Joly V, et al. Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases. Journal of clinical microbiology. 2018;56(6).
21. Pellet C, Chevret S, Frances C, Euvrard S, Hurault M, Legendre C, et al. Prognostic value of quantitative Kaposi sarcoma--associated herpesvirus load in posttransplantation Kaposi sarcoma. The Journal of infectious diseases. 2002;186(1):110-3.
22. Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. Journal of clinical microbiology. 2001;39(12):4269-73.
23. Borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010;51(3):342-9.
24. Campbell TB, Borok M, White IE, Gudza I, Ndemera B, Taziwa A, et al. Relationship of Kaposi sarcoma (KS)-associated herpesvirus viremia and KS disease in Zimbabwe. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003;36(9):1144-51.
25. Laney AS, Cannon MJ, Jaffe HW, Offermann MK, Ou CY, Radford KW, et al. Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. Aids. 2007;21(12):1541-5.
26. Nsubuga MM, Biggar RJ, Combs S, Marshall V, Mbisa G, Kambugu F, et al. Human herpesvirus 8 load and progression of AIDS-related Kaposi sarcoma lesions. Cancer letters. 2008;263(2):182-8.
27. Polstra AM, Cornelissen M, Goudsmit J, van der Kuyl AC. Retrospective, longitudinal analysis of serum human herpesvirus-8 viral DNA load in AIDS-related Kaposi's sarcoma patients before and after diagnosis. Journal of medical virology. 2004;74(3):390-6.
28. Hulaniuk ML, Torres O, Bartoli S, Fortuny L, Burgos Pratx L, Nunez F, et al. Increased prevalence of human herpesvirus type 8 (HHV-8) genome among blood donors from North-Western Argentina. Journal of medical virology. 2017;89(3):518-27.
29. Enbom M, Urassa W, Massambu C, Thorstensson R, Mhalu F, Linde A. Detection of human herpesvirus 8 DNA in serum from blood donors with HHV-8 antibodies indicates possible bloodborne virus transmission. Journal of medical virology. 2002;68(2):264-7.
30. Hudnall SD, Chen T, Rady P, Tyring S, Allison P. Human herpesvirus 8 seroprevalence and viral load in healthy adult blood donors. Transfusion. 2003;43(1):85-90.
31. Shebl FM, Emmanuel B, Bunts L, Biryahwaho B, Kiruthu C, Huang ML, et al. Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma among Ugandans. Journal of medical virology. 2013;85(9):1602-10.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

32. Nalwoga A, Cose S, Wakeham K, Miley W, Ndibazza J, Drakeley C, et al. Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Tropical medicine & international health : TM & IH. 2015;20(5):665-72.
33. Wakeham K, Webb EL, Sebina I, Muhangi L, Miley W, Johnson WT, et al. Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women. Infectious agents and cancer. 2011;6(1):15.
34. Wakeham K, Webb EL, Sebina I, Nalwoga A, Muhangi L, Miley W, et al. Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda. J Acquir Immune Defic Syndr. 2013;63(2):228-33.
35. Newton R, Labo N, Wakeham K, Marshall V, Roshan R, Nalwoga A, et al. Determinants of gamma-herpesvirus shedding in saliva among Ugandan children and their mothers. The Journal of infectious diseases. 2018.
36. Bender Ignacio RA, Goldman JD, Magaret AS, Selke S, Huang ML, Gantt S, et al. Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. Infectious agents and cancer. 2016;11:7.
37. de Sanjose S, Marshall V, Sola J, Palacio V, Almirall R, Goedert JJ, et al. Prevalence of Kaposi's sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. International journal of cancer Journal international du cancer. 2002;98(1):155-8.
38. Newton R, Labo N, Wakeham K, Marshall V, Roshan R, Nalwoga A, et al. Determinants of Gammaherpesvirus Shedding in Saliva Among Ugandan Children and Their Mothers. The Journal of infectious diseases. 2018;218(6):892-900.
39. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay. Journal of virological methods. 2001;91(2):109-17.
40. Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M, et al. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS pathogens. 2014;10(3):e1004046.
41. Nalwoga A, Miley W, Labo N, Elliott A, Cose S, Whitby D, et al. Age of Infection with Kaposi Sarcoma Associated Herpesvirus and Subsequent Antibody Values Among Children in Uganda. The Pediatric infectious disease journal. 2018.
42. Mbisa GL, Miley W, Gamache CJ, Gillette WK, Esposito D, Hopkins R, et al. Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. Journal of immunological methods. 2010;356(1-2):39-46.
43. Bukusuba JW, Hughes P, Kizza M, Muhangi L, Muwanga M, Whitworth JA, et al. Screening for intestinal helminth infection in a semi-urban cohort of pregnant women in Uganda. Tropical doctor. 2004;34(1):27-8.
44. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de Sao Paulo. 1972;14(6):397-400.
45. Blackbourn DJ, Lennette ET, Ambroziak J, Mourich DV, Levy JA. Human herpesvirus 8 detection in nasal secretions and saliva. The Journal of infectious diseases. 1998;177(1):213-6.
46. Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, Schacker T, et al. Mucosal shedding of human herpesvirus 8 in men. The New England journal of medicine. 2000;343(19):1369-77.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

47. Triantos D, Horefti E, Paximadi E, Kyriakopoulou Z, Karakassiliotis G, Papanastasiou K, et al. Presence of human herpes virus-8 in saliva and non-lesional oral mucosa in HIV-infected and oncologic immunocompromised patients. Oral microbiology and immunology. 2004;19(3):201-4.
48. Whitby D, Marshall VA, Bagni RK, Miley WJ, McCloud TG, Hines-Boykin R, et al. Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. International journal of cancer Journal international du cancer. 2007;120(2):321-8.
49. Borges JD, Souza VA, Giambartolomei C, Dudbridge F, Freire WS, Gregorio SA, et al. Transmission of human herpesvirus type 8 infection within families in american indigenous populations from the Brazilian Amazon. The Journal of infectious diseases. 2012;205(12):1869-76.
50. Olp LN, Shea DM, White MK, Gondwe C, Kankasa C, Wood C. Early childhood infection of Kaposi's sarcoma-associated herpesvirus in Zambian households: a molecular analysis. International journal of cancer Journal international du cancer. 2013;132(5):1182-90.
51. Kijogi C, Kimura D, Bao LQ, Nakamura R, Chadeka EA, Cheruiyot NB, et al. Modulation of immune responses by Plasmodium falciparum infection in asymptomatic children living in the endemic region of Mbita, western Kenya. Parasitology international. 2018;67(3):284-93.
52. Loughland JR, Woodberry T, Boyle MJ, Tipping PE, Piera KA, Amante FH, et al. Plasmodium falciparum activates CD16+ dendritic cells to produce TNF and IL-10 in subpatent malaria. The Journal of infectious diseases. 2018.
53. Biryahwaho B, Dollard SC, Pfeiffer RM, Shebl FM, Munuo S, Amin MM, et al. Sex and geographic patterns of human herpesvirus 8 infection in a nationally representative population-based sample in Uganda. The Journal of infectious diseases. 2010;202(9):1347-53.
54. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
55. Wakeham K, Johnston WT, Nalwoga A, Webb EL, Mayanja BN, Miley W, et al. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study. International journal of cancer Journal international du cancer. 2015;136(12):2822-30.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Figure legends

Figure 1: KSHV viral load in saliva and in peripheral blood mononuclear cells (PBMCs). KSHV viral loads were measured using real time PCR.

Figure 2: Proportion of individuals with detectable KSHV in peripheral blood mononuclear cells (PBMCs) (A) and saliva (B). KSHV viral loads were measured using real time PCR.

Supplementary Figure 1: IgG antibody levels to K8.1 (A & B) and ORF73 (C& D) protein among individuals with and without detectable KSHV in blood (A & C) and in saliva (B & D). Antibodies were measured using Luminex assay. These antibodies were $\log_{10}$ transformed. P values were obtained from a ttest after $\log_{10}$ transformation of the data.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Table 1: General characteristics and parasite infections status among participants tested for KSHV viral DNA

Sex, males	49% (410/834)
Age, mean (range)	36 (3-89)
Age groups	
2-5	3% (27/840)
6-12	11% (95/840)
13-18	13% (110/840)
19-25	8% (67/840)
26-35	17% (139/840)
36-45	14% (121/840)
46-55	14% (118/840)
56-65	9% (74/840)
66-89	11% (89/840)
Malaria parasitaemia	
Overall	4% (34/834)
Children aged 3-12 years	11% (13/120)
Schistosoma mansoni infection status	1% (7/686)
Hookworm infection status	15% (104/686)
Ascaria lumbricoides infection status	1% (8/686)
Trichuris trichiura infection status	0.2% (1/685)

Malaria parasitaemia was determined using rapid diagnostic tests (RDTs). Helminth status was determined from a single stool sample using Kato Katz method.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Table 2: Risk factors for the presence of detectable KSHV DNA in blood (categorically)

	% detectable viral DNA in blood	OR[a] (95% CI)	P value	Adjusted[b] OR (95% CI)	P value
Age group					
3-12	23% (27/120)	1		1	
13-25	15% (26/177)	0.59 (0.33, 1.08)		0.63 (0.33, 1.17)	
26-50	7% (20/307)	0.24 (0.13, 0.45)		0.29 (0.15, 0.57)	
50+	8% (18/227)	0.30 (0.16, 0.57)	<0.0001	0.34 (0.16, 0.72)	0.0014
Sex					
Female	10% (41/419)	1		1	
Male	12% (49/406)	1.27 (0.82, 1.96)	0.294	0.89 (0.55, 1.45)	0.638
Malaria parasiatemia					
Negative	10% (83/791)	1		1	
Positive	21% (7/34)	2.21 (0.93, 5.24)	0.071	1.59 (0.64, 3.95)	0.321
S. mansoni					
Negative	11% (77/672)	1		1	
Positive	43% (3/7)	5.80 (1.27, 26.38)	0.023	11.04 (2.16, 56.97)	0.004
Hookworm					
Negative	13% (74/576)	1		1	
Positive	6% (6/103)	0.42 (0.18, 0.99)	0.048	0.41 (0.16, 1.04)	0.061

[a] OR: odds ratio, [b] adjusted for age, sex, malaria parasitaemia, *S. mansoni* and hookworm infection status. Logistic regression was used for statistical analysis. Malaria parasitaemia was determined using rapid diagnostic tests (RDTs). Helminth status was determined from a single stool sample using Kato Katz method.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Table 3: Risk factors associated with increasing levels of KSHV DNA in blood (continuously)

	Coef[a]. (95% CI)	P value	Adjusted[b] Coef. (95% CI)	P value
Age group				
3-12	Ref		Ref	
13-25	-0.39 (-0.86, 0.07)		-0.35 (-0.84, 0.15)	
26-50	0.19 (-0.31, 0.69)		0.26 (-0.30, 0.83)	
50+	-0.32 (-0.83, 0.19)	0.084	-0.06 (-0.70, 0.57)	0.160
Sex				
Female	Ref		ref	
Male	0.10 (-0.27, 0.47)	0.594	0.21 (-0.19, 0.61)	0.292
Malaria parasitaemia				
Negative	Ref		Ref	
Positive	0.71 (0.05, 1.38)	0.036	0.79 (0.07, 1.50)	0.031
S. mansoni				
Negative	Ref		Ref	
Positive	0.17 (-0.87, 1.21)	0.750	-0.15 (-1.30, 1.00)	0.797
Hookworm				
Negative	Ref		Ref	
Positive	0.30 (-0.45, 1.05)	0.79	0.37 (-0.46, 1.21)	0.372

[a] Coef: linear regression coefficient, [b] adjusted for age, sex, malaria parasitaemia, *S. mansoni* and hookworm infection status. Linear regression modelling was performed on $\log_{10}$ transformed KSHV DNA levels for statistical analysis. Malaria parasitaemia was determined using rapid diagnostic tests (RDTs). Helminth status was determined from a single stool sample using Kato Katz method.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Table 4: Risk factors for the presence of detectable KSHV DNA in saliva (categorically)

	% detectable viral DNA in saliva	OR[a] (95% CI)	P value	Adjusted[b] OR (95% CI)	P value
Age group					
3-12	42% (50/120)	1			
13-25	31% (55/175)	0.64 (0.40, 1.40)		0.61 (0.37, 1.02)	
26-50	18% (56/310)	0.31 (0.19, 0.49)		0.38 (0.24, 0.63)	
50+	17% (39/231)	0.28 (0.18, 0.47)	<0.0001	0.30 (0.18, 0.54)	0.0001
Sex					
Female	19% (79/423)	1		1	
Male	29% (119/407)	1.80 (1.30, 2.49)	<0.0001	1.63 (1.14, 2.34)	0.008
Malaria parasitaemia					
Negative	24% (188/796)	1		1	
Positive	29% (10/34)	1.35 (0.63, 2.87)	0.439	0.98 (0.44, 2.16)	0.952
S. mansoni					
Negative	26% (174/675)	1		1	
positive	43% (3/70)	2.16 (0.48, 9.74)	0.317	2.43 (0.51, 11.52)	0.265
Hookworm					
Negative	27% (158/578)	1		1	
Positive	18% (19/104)	0.59 (0.35, 1.009)	0.054	0.66 (0.38, 1.14)	0.136

[a] OR: odds ratio, [b] adjusted for age, sex, malaria parasitaemia, *S. mansoni* and hookworm infection status. Logistic regression was used for statistical analysis. Malaria parasitaemia was determined using rapid diagnostic tests (RDTs). Helminth status was determined from a single stool sample using Kato Katz method.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Table 5: Risk factors associated with levels of KSHV DNA in saliva (continuously)

	Coef.[a] (95% CI)	P value	Adjusted[b] Coef. (95% CI)	P value
Age group				
3-12	Ref		Ref	
13-25	-0.50 (-1.02, 0.21)		-0.61 (-0.13, -0.09)	
26-50	-0.31 (-0.82, 0.21)		-0.26 (-0.80, 0.28)	
50+	-0.78 (-1.35, -0.21)	0.049	-0.76 (-1.40, -0.11)	0.048
Sex				
Female	Ref		Ref	
Male	0.51 (0.12, 0.89)	0.010	0.46 (0.05, 0.87)	0.027
Malaria parasitaemia				
Negative	Ref		Ref	
Positive	0.20 (-0.67, 1.07)	0.651	0.05 (-0.82, 0.92)	0.909
S. mansoni				
Negative	Ref		Ref	
positive	-0.58 (-2.12, 0.96)	0.460	-0.38 (-1.94, 1.18)	0.635
Hookworm				
Negative	Ref		Ref	
Positive	-0.36 (-0.96, 0.32)	0.326	-0.37 (-1.03, 0.29)	0.270

[a] Coef: linear regression coefficient, [b] adjusted for age, sex, malaria parasitaemia, *S. mansoni* and hookworm infection status. Linear regression modelling was performed on log_{10} transformed KSHV DNA levels for statistical analysis. Malaria parasitaemia was determined using rapid diagnostic tests (RDTs). Helminth status was determined from a single stool sample using Kato Katz method.

Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Figure 1



Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019

Figure 2



Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz916/5573921 by London School of Hygiene & Tropical Medicine user on 27 September 2019